162 related articles for article (PubMed ID: 36046982)
1. Probability of Target Attainment Analyses to Inform Ceftolozane/Tazobactam Dosing Regimens for Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia and End-Stage Renal Disease Receiving Intermittent Hemodialysis.
Feng HP; Patel YT; Zhang Z; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda C; Gao W
J Clin Pharmacol; 2023 Feb; 63(2):166-171. PubMed ID: 36046982
[TBL] [Abstract][Full Text] [Related]
2. Ceftolozane/Tazobactam Probability of Target Attainment in Patients With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
Gao W; Patel YT; Zhang Z; Johnson MG; Fiedler-Kelly J; Bruno CJ; Rhee EG; Anda C; Feng HP
J Clin Pharmacol; 2023 Mar; 63(3):352-357. PubMed ID: 36201105
[TBL] [Abstract][Full Text] [Related]
3. Exposure-Efficacy Analyses Support Optimal Dosing Regimens of Ceftolozane/Tazobactam in Participants with Hospital-Acquired/Ventilator-Associated Bacterial Pneumonia in ASPECT-NP.
Gao W; Passarell J; Patel YT; Zhang Z; Lin G; Fiedler-Kelly J; Bruno CJ; Rhee EG; De Anda CS; Feng HP
Antimicrob Agents Chemother; 2022 May; 66(5):e0139921. PubMed ID: 35471040
[TBL] [Abstract][Full Text] [Related]
4. Outcomes in participants with failure of initial antibacterial therapy for hospital-acquired/ventilator-associated bacterial pneumonia prior to enrollment in the randomized, controlled phase 3 ASPECT-NP trial of ceftolozane/tazobactam versus meropenem.
Kollef MH; Timsit JF; Martin-Loeches I; Wunderink RG; Huntington JA; Jensen EH; Yu B; Bruno CJ
Crit Care; 2022 Dec; 26(1):373. PubMed ID: 36457059
[TBL] [Abstract][Full Text] [Related]
5. Ceftolozane/tazobactam probability of target attainment and outcomes in participants with augmented renal clearance from the randomized phase 3 ASPECT-NP trial.
Shorr AF; Bruno CJ; Zhang Z; Jensen E; Gao W; Feng HP; Huntington JA; Yu B; Rhee EG; De Anda C; Basu S; Kollef MH
Crit Care; 2021 Oct; 25(1):354. PubMed ID: 34600585
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetic Analysis for Plasma and Epithelial Lining Fluid Ceftolozane/Tazobactam Concentrations in Patients With Ventilated Nosocomial Pneumonia.
Zhang Z; Patel YT; Fiedler-Kelly J; Feng HP; Bruno CJ; Gao W
J Clin Pharmacol; 2021 Feb; 61(2):254-268. PubMed ID: 32949031
[TBL] [Abstract][Full Text] [Related]
7. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Xiao AJ; Miller BW; Huntington JA; Nicolau DP
J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence.
Martin-Loeches I; Bruno CJ; DeRyke CA
Future Microbiol; 2024; 19(6):465-480. PubMed ID: 38252038
[TBL] [Abstract][Full Text] [Related]
9. Ceftolozane-tazobactam for the treatment of multidrug-resistant
Alessa MA; Almangour TA; Alhossan A; Alkholief MA; Alhokail M; Tabb DE
Am J Health Syst Pharm; 2018 May; 75(9):e184-e188. PubMed ID: 29691260
[TBL] [Abstract][Full Text] [Related]
10. Ceftolozane/tazobactam for hospital-acquired/ventilator-associated bacterial pneumonia due to ESBL-producing Enterobacterales: a subgroup analysis of the ASPECT-NP clinical trial.
Paterson DL; Bassetti M; Motyl M; Johnson MG; Castanheira M; Jensen EH; Huntington JA; Yu B; Wolf DJ; Bruno CJ
J Antimicrob Chemother; 2022 Aug; 77(9):2522-2531. PubMed ID: 35781341
[TBL] [Abstract][Full Text] [Related]
11. Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial.
Timsit JF; Huntington JA; Wunderink RG; Shime N; Kollef MH; Kivistik Ü; Nováček M; Réa-Neto Á; Martin-Loeches I; Yu B; Jensen EH; Butterton JR; Wolf DJ; Rhee EG; Bruno CJ
Crit Care; 2021 Aug; 25(1):290. PubMed ID: 34380538
[TBL] [Abstract][Full Text] [Related]
12. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial.
Kollef MH; Nováček M; Kivistik Ü; Réa-Neto Á; Shime N; Martin-Loeches I; Timsit JF; Wunderink RG; Bruno CJ; Huntington JA; Lin G; Yu B; Butterton JR; Rhee EG
Lancet Infect Dis; 2019 Dec; 19(12):1299-1311. PubMed ID: 31563344
[TBL] [Abstract][Full Text] [Related]
13. Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection.
Xiao AJ; Huntington JA; Long J; Caro L
Int J Antimicrob Agents; 2018 Sep; 52(3):324-330. PubMed ID: 29596902
[TBL] [Abstract][Full Text] [Related]
14. Clinical and microbiological outcomes, by causative pathogen, in the ASPECT-NP randomized, controlled, Phase 3 trial comparing ceftolozane/tazobactam and meropenem for treatment of hospital-acquired/ventilator-associated bacterial pneumonia.
Martin-Loeches I; Timsit JF; Kollef MH; Wunderink RG; Shime N; Nováček M; Kivistik Ü; Réa-Neto Á; Bruno CJ; Huntington JA; Lin G; Jensen EH; Motyl M; Yu B; Gates D; Butterton JR; Rhee EG
J Antimicrob Chemother; 2022 Mar; 77(4):1166-1177. PubMed ID: 35022730
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal Infections.
Larson KB; Patel YT; Willavize S; Bradley JS; Rhee EG; Caro L; Rizk ML
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962340
[TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli.
Zhanel GG; Chung P; Adam H; Zelenitsky S; Denisuik A; Schweizer F; Lagacé-Wiens PR; Rubinstein E; Gin AS; Walkty A; Hoban DJ; Lynch JP; Karlowsky JA
Drugs; 2014 Jan; 74(1):31-51. PubMed ID: 24352909
[TBL] [Abstract][Full Text] [Related]
17. PK/PD Target Attainment With Ceftolozane/Tazobactam Using Monte Carlo Simulation in Patients With Various Degrees of Renal Function, Including Augmented Renal Clearance and End-Stage Renal Disease.
Xiao AJ; Caro L; Popejoy MW; Huntington JA; Kullar R
Infect Dis Ther; 2017 Mar; 6(1):137-148. PubMed ID: 28013453
[TBL] [Abstract][Full Text] [Related]
18. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia.
Caro L; Nicolau DP; De Waele JJ; Kuti JL; Larson KB; Gadzicki E; Yu B; Zeng Z; Adedoyin A; Rhee EG
J Antimicrob Chemother; 2020 Jun; 75(6):1546-1553. PubMed ID: 32211756
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of tazobactam/ceftolozane in Japanese patients with complicated urinary tract infection and complicated intra-abdominal infection.
Kakara M; Larson K; Feng HP; Shiomi M; Yoshitsugu H; Rizk ML
J Infect Chemother; 2019 Mar; 25(3):182-191. PubMed ID: 30528208
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of CTZ/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan.
Takaya R; Mori N; Saito E; Ohde S
BMC Health Serv Res; 2024 Mar; 24(1):389. PubMed ID: 38549158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
